logo
  

Finland Industrial Production Logs Sharp Decline In March

Finland's industrial production declined sharply in March due to political industrial action and maintenance shutdowns, data from Statistics Finland showed on Wednesday.

Industrial output decreased 3.9 percent on a monthly basis after a 0.2 percent drop.

Among main industries, only mining and quarrying and the food industry had more production than in the previous month.

The statistical office said the industrial actions had the strongest impact on the forest industry. At the same time, the fall in electricity, gas, steam and air conditioning supply was also caused by maintenance shutdowns.

Year-on-year, industrial production declined 7.7 percent, in contrast to the 1.5 percent rise in the previous month.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT